A new technology to measure how drugs bind to important proteins in cells
Official title: Spotting-free Nano-Oscillator Array for Quantification of Virion Displayed Membrane Protein Binding Kinetics
Funded at Biosensing Instrument, INC. · NIH-11070131 · Data updated 2026-11-12
This study is testing a new technology that helps scientists better understand how drugs interact with important proteins in our cells, which could lead to better cancer treatments and faster drug development.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biosensing Instrument, INC. NIH-funded |
| Lab location | 1 site (Tempe, United States) |
| Project start | April 2, 2025 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $349,566 |
| NIH project number | 1R42GM157918-01 |
| Project ID | NIH-11070131 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that are being targeted by new drug therapies, particularly those involving G-protein-coupled receptors.
✕Less likely to help
Patients with conditions unrelated to transmembrane proteins or those not involved in drug development may not benefit from this research.
What this research studies
This research focuses on developing a novel technology called Spotting-Free Nano-Oscillator Array (SFNOA) to measure the binding kinetics of drugs to transmembrane proteins, which are crucial for many cellular functions and are key targets in cancer treatment. The approach aims to overcome existing challenges in accurately measuring these interactions by allowing for high throughput and label-free quantification of ligand binding in the proteins' native states. By utilizing virion displayed transmembrane proteins, the research seeks to maintain the proteins' natural conformations, which is essential for understanding their function and improving drug development. This innovative method could significantly enhance the efficiency of drug discovery processes.
Why it matters
Potential benefit: If successful, this research could lead to more effective drug development for cancer and other diseases by providing better insights into how drugs interact with their targets.
How similar studies have gone: While the approach is innovative, similar technologies have shown promise in drug binding studies, indicating potential for success.
Where this research is happening
-
Biosensing Instrument, INC.
Tempe, United States Active
Researchers
- Principal investigator: Ly, Nguyen — Biosensing Instrument, INC.
- Study coordinator: Ly, Nguyen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.